Dr Reddys Laboratories annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Dr Reddys Laboratories Stock-Based Compensation Growth & History (RDY)
Dr Reddys Laboratories's stock-based compensation was $5.0M for fiscal 2025.
View full Dr Reddys Laboratories company overviewDr Reddys Laboratories annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | $5.0M | $0 | 0.00% |
| 2024 | 2024-03-31 | $5.0M | $0 | 0.00% |
| 2023 | 2023-03-31 | $5.0M | −$3.0M | −37.50% |
| 2022 | 2022-03-31 | $8.0M | $0 | 0.00% |
| 2021 | 2021-03-31 | $8.0M | $1.0M | +14.29% |
| 2020 | 2020-03-31 | $7.0M | $1.0M | +16.67% |
| 2019 | 2019-03-31 | $6.0M | −$1.0M | −14.29% |
| 2018 | 2018-03-31 | $7.0M | — | — |
Dr Reddys Laboratories stock-based compensation trends
Over the last five fiscal years, Dr Reddys Laboratories's stock-based compensation decreased from $7.0M to $5.0M, a change of −$2.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dr Reddys Laboratories source filings ↗